Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared Reveal Genomics‘ post on LinkedIn, adding:
“A very special moment for REVEAL GENOMICS
Built on years of shared work, trust, and a common vision. Deeply grateful to our team, our founders, our investors, and the institutions behind us for their continued trust and long-term commitment to rigorous, clinically meaningful genomics. Proud of what we have built together, and excited for what is ahead!”
Quoting Reveal Genomics‘ post:
“We are pleased to share that REVEAL GENOMICS has strengthened its leadership framework to better align founder leadership with our strategic priorities, reinforcing our commitment to long-term growth, scientific excellence, and global clinical impact.
We have appointed our co-founders to key leadership roles: Joel Parker, as Chief Scientific Officer; Ana Vivancos Prellezo, as Director of NGS and Genomic Technologies; and Aleix Prat as Chairman of the Board of Directors. These appointments strengthen governance and ensure close alignment across scientific, technological, and strategic areas as we expand internationally.
Through this leadership alignment, we continue to support the development, validation, and global adoption of our genomic assays, advancing precision oncology through rigorous science, innovation, and clinical relevance. ”
Read the Press Release
More posts featuring Alex Prat and Reveal Genomics.